Brain-derived neurotrophic factor (BDNF) promotes maturation of cholinergic neurons. However, how activity-dependent BDNF expression affects specific cholinergic gene expression remains unclear. This study addressed this question by determining mRNA levels of 22 acetylcholine receptor subunits, the choline transporter (CHT), and the choline acetyltransferase (ChAT) in mice deficient in activity-dependent BDNF via promoter IV (KIV) and control wild-type mice. Quantitative RT-PCR revealed significant reductions in nicotinic acetylcholine receptor alpha 5 (CHRNA5) in the frontal cortex and hippocampus and M5 muscarinic acetylcholine receptor (CHRM5) in the hippocampus, but significant increases in M2 muscarinic acetylcholine receptor (CHRM2) in the frontal cortex of KIV mice compared to wild-type mice. Three-week treatments with fluoxetine, phenelzine, duloxetine, imipramine, or an enriched environment treatment (EET) did not affect the altered expression of these genes except that EET increased CHRNA5 levels only in KIV frontal cortex. EET also increased levels of CHRNA7, CHT, and ChAT, again only in the KIV frontal cortex. The imipramine treatment was most prominent among the four antidepressants; it upregulated hippocampal CHRM2 and frontal cortex CHRM5 in both genotypes, and frontal cortex CHRNA7 only in KIV mice. To the best of our knowledge, this is the first evidence that BDNF deficiency disturbs expression of CHRNA5, CHRM2, and CHRM5. Our results suggest that promoter IV-BDNF deficiency -which occurs under chronic stress -causes cholinergic dysfunctions via these receptors. EET is effective on CHRNA5, while its compensatory induction of other cholinergic genes or drugs targeting CHRNA5, CHRM2, and CHRM5 may become an alternative strategy to reverse these BDNF-linked cholinergic dysfunctions.
promoters, promoter IV (classified as promoter III prior to 2007) is most responsive to neuronal activity to induce BDNF expression (Timmusk et al. 1993; Shieh et al. 1998; Tao et al. 1998) . However, promoter IV undergoes epigenetic inactivation by chronic stress or early-life maltreatment (Tsankova et al. 2006; Fuchikami et al. 2009; Roth et al. 2009 ). Reductions in BDNF levels and inactivation of promoter IV have been observed in many cognitive and emotional disorders, such as schizophrenia (Weickert et al. 2003; Hashimoto et al. 2005; Wong et al. 2010) , depression (Dwivedi et al. 2003; Keller et al. 2010; Hing et al. 2012) , and Alzheimer's disease (Phillips et al. 1991; Murray et al. 1994; Ferrer et al. 1999; Holsinger et al. 2000; Garzon et al. 2002) . To investigate the consequent dysfunctions caused by deficiency of activity-dependent expression of BDNF, we have generated knock-in mice that lack promoter IV-driven BDNF expression [knockin-promoter IV (KIV)] (Sakata et al. 2009 ). Using KIV mice, we recently showed causal evidence that a deficiency of activity-dependent promoter IVdriven BDNF expression (promoter IV-BDNF) leads to depression-like behavior and cognitive dysfunctions, including decreased exploratory activity, stress-induced despair, anhedonia, anxiety-like behavior, inflexibility in reversal learning and fear extinction, and impaired response inhibition (Sakata et al. 2010 (Sakata et al. , 2013a .
In KIV mice, activity-dependent expression of BDNF protein is particularly abolished in the CA1 region of the hippocampus (Sakata et al. 2013a ) and the medial prefrontal cortex (mPFC) (Sakata et al. 2009 ). The basal levels of BDNF protein (without any stimulation) are also reduced in the hippocampus and frontal cortex (53% and 41% reduction, respectively), which likely reflect the lack of promoter IV-BDNF in response to the basal activity of animals (moving, grooming, food taking, etc.) (Sakata et al. 2009 (Sakata et al. , 2013a . The reductions may also reflect reduced BDNF expression driven by other promoters (Martinowich et al. 2011 ) because of reduced feed-forward BDNF transcription induced by BDNF itself (Yasuda et al. 2007; Sakata 2011; Sakata and Duke 2014) and possible promoter interaction (Maynard et al. 2016) , while the transcriptional functions of other BDNF promoters are intact (Sakata et al. 2009 (Sakata et al. , 2013b Jha et al. 2011) . KIV mice lack promoter IV-BDNF from the start of life. This condition mimics the epigenetic condition caused by maternal depression and early-life stress that reduces promoter IV-BDNF and lasts throughout the lifespan and across generations (Onishchenko et al. 2008; Roth et al. 2009 ). KIV mice show no obvious structural changes in both hippocampus and frontal cortex at the young adult stage (Sakata et al. 2009 (Sakata et al. , 2013a . However, they show impaired long-term synaptic plasticity (> 3 h) in the hippocampal CA1 region (Sakata et al. 2013a ) and aberrant spike-timing dependent plasticity in the mPFC (Sakata et al. 2009 ). The promoter IV-BDNF deficiency impairs GABAergic functions (Hong et al. 2008) particularly in the mPFC (Sakata et al. 2009 ), while keeping basic glutamatergic functions intact (Sakata et al. 2009 (Sakata et al. , 2013a . This deficiency also disturbs expression of GABA-related Tripp et al. 2012; Maynard et al. 2016) and monoamine-related genes (Sakata and Duke 2014) .
One neurotransmitter system that is likely affected by activity-dependent BDNF expression, but is still unclear, is the cholinergic system. Acetylcholine is implicated in cognitive functions and reward/motor activity (Sarter and Parikh 2005) and is a treatment target for many psychiatric and neurological disorders, such as schizophrenia, depression, attention deficit hyperactivity (ADHD), and Alzheimer's disease (Court et al. 2001; Hellstrom-Lindahl et al. 2004 ; Levin et al. 2006; Olincy et al. 2006; Taly et al. 2009; Srivareerat et al. 2011; Lewis and Picciotto 2013; Parikh et al. 2016) . Previous studies have shown reciprocal regulation between acetylcholine and BDNF. Basal forebrain cholinergic neurons that release acetylcholine project to the cortex and hippocampus (Sarter and Parikh 2005) , where BDNF mRNA is expressed and regulated by acetylcholine input (Phillips et al. 1990; Lindefors et al. 1992; Lapchak et al. 1993; Mahy et al. 1996; Berchtold et al. 2002) . For example, hippocampal BDNF mRNA expression is induced by activation of muscarinic acetylcholine receptors (mAChRs) (Lapchak et al. 1993; Knipper et al. 1994) and by subchronic activation of nicotinic acetylcholine receptors (nAChRs) (Kenny et al. 2000; Hellstrom-Lindahl et al. 2004; Srivareerat et al. 2011) , whereas BDNF expression is decreased by acute activation of nAChRs (Kenny et al. 2000) . By contrast, BDNF promotes survival and differentiation of cholinergic neurons (Knusel et al. 1991; Klein et al. 1999 ) and the release of acetylcholine (Knipper et al. 1994; Auld et al. 2001) . Cooperation between cholinergic and glutamatergic receptors has been found to be essential for the induction of BDNF-dependent long-lasting synaptic plasticity (Navakkode and Korte 2012) .
The importance of BDNF in the cholinergic system has been reported for more than two decades. Yet, BDNF regulation of the specific cholinergic gene expression remains unclear. The cholinergic system is divergent, having 5 muscarinic and 17 nicotinic receptors that each has distinct functions and distributions (Boulter et al. 1986; Caulfield 1993; Gotti et al. 2006; Taly et al. 2009 ). Only limited reports have shown effects of BDNF on expression of individual cholinergic genes: BDNF null deficiency reduces choline acetyltransferase (ChAT) expression in the medial septum (Ward and Hagg 2000) and BDNF reduces (Fernandes et al. 2008) or increases alpha7 nAChRs expression in hippocampal interneurons (Massey et al. 2006) . The effects of deficiency of activity-dependent BDNF expression on the diverse cholinergic molecules remain unknown. In this study, we addressed this issue by determining changes in mRNA levels of 22 acetylcholine receptors, the choline transporter (CHT), and the acetylcholine synthesizing enzyme (ChAT) in KIV mice, compared to control wild-type (WT) mice using quantitative reverse transcription polymerase chain reaction (qRT-PCR). We focused on the frontal cortex and hippocampus, because these are the target regions of basal forebrain cholinergic neurons (Phillips et al. 1990; Sarter and Parikh 2005) and the regions where defective promoter IV largely abolish activity-driven BDNF expression (Sakata et al. 2009 (Sakata et al. , 2013a Sakata 2011) . We also explored the effects of chronic drug and environmental treatments on the affected expression of acetylcholine-related genes. We used four different types of antidepressants -fluoxetine (a selective serotonin reuptake inhibitor: SSRI), phenelzine (a monoamine oxidase inhibitor), duloxetine (a serotoninnorepinephrine reuptake inhibitor: SNRI), and imipramine (a tricyclic antidepressant) -or an enriched environment treatment (EET). This was because we have previously shown that these treatments partially or completely normalize depression-like behavior of KIV mice, while EET, but not antidepressant treatment, normalizes hippocampal BDNF levels (Jha et al. 2011 (Jha et al. , 2016 Sakata et al. 2013b) . We asked whether changes in acetylcholine gene expression were involved in the treatment effects.
Materials and methods

Animals
The generation of BDNF promoter IV knock-in (KIV) mice has been described previously (Sakata et al. 2009 ). Briefly, the BDNF promoter/exon IV DNA region was cloned and a green fluorescent protein gene with a stop codon was inserted into exon IV to disrupt promoter IV-driven expression of BDNF protein. The construct was used for homologous recombination in 129/sv embryonic stem cells (from NIH). The embryonic stem cells and C57BL/6J blastocytes were used to generate chimeric mice, which were crossed to C57BL/ 6J females for > 12 generations. Adult (2-3 months old) gendermatched pairs of KIV and control WT mice were used. Five pairs (two males and three females for each genotype) were used for initial screening. Ten pairs of another cohort (five males and five females for each genotype) were used to confirm effects of promoter IV-BDNF deficiency. Six pairs of another cohort (three males and three females for each genotype) were randomly assigned to each treatment using randomization table. The sample size was determined based on the previous studies (Jha et al. 2011; Sakata et al. 2013b; Sakata and Duke 2014) . All animals were housed in a group in a normal 12:12 h dark-light cycle and had ad libitum access to food and water. All animal experiments were approved by the University of Tennessee Laboratory Animal Care and Use Committee and were conducted in accordance with NIH guidelines.
Drug treatment
Mice received 21 days of four different types of antidepressants as described previously (Sakata et al. 2013b) . Briefly, mice received a single intraperitoneal (i.p.) injection per day with saline or with one of the four different classes of antidepressant: fluoxetine (10 mg/kg, Mallinckrodt, Inc., Hazelwood, MO, USA), phenelzine (10 mg/kg, Sigma, St. Louis, MO, USA), duloxetine (20 mg/kg, Eli Lilly, Indianapolis, IN, USA), and imipramine (10 mg/kg, Sigma). Animals were killed 3 h after the last injection. The method of drug administration (i.p.), the dosage, and the time of killing were decided based on previous studies (Nibuya et al. 1995; Dwivedi et al. 2006; Khundakar and Zetterstrom 2006; Tsankova et al. 2006; Mannari et al. 2008; Molteni et al. 2009 ).
Enriched environment treatment (EET)
Mice received 21 days of standard condition treatment (SCT) or EET, as described previously (Jha et al. 2011) . Briefly, SCT consisted of a regular cage (27 9 16 9 12 cm) containing 2-5 mice (group-housed to avoid isolation stress). EET consisted of a larger cage (44 9 22 9 16 cm) containing one plastic running wheel per five mice to increase physical exercise, an assortment of toys (igloo, dome, balls, tunnels, etc.) weekly changed, Foraging Crumble (Bio-Serv, Frenchtown, NJ, USA) to increase perception/ mental exercise, and 5-10 company mice with nesting material to increase social interaction.
Tissue collection, RNA extraction, and qRT-PCR Each animal was killed by i.p. injections of 90 mg/kg ketamine and 10 mg/kg of xylazine. The hippocampus and frontal cortex were removed and immediately frozen, within 6 min after the killing, and stored at À80°C until RNA extraction. Total RNA was extracted from the tissues using QIAshredder (Qiagen, Valencia, CA, USA) and RNeasy Kit (Qiagen) with on-column DNase (Qiagen), and quantified using the NanoDrop spectrophotometer (Agilent Technologies, Santa Clara, CA, USA), as described previously (Sakata and Duke 2014) . One microgram of total RNA was reverse transcribed into single-strand cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN, USA). qRT-PCR was performed using BioMark, as described previously (Reiner et al. 2012; Sakata and Duke 2014) . Briefly, a 0.5 lL sample of the cDNA (from 25 ng of total RNA) was preamplified for 14 cycles, then the diluted (1 : 5) reactions were used for qPCR using 96.96 dynamic array chips (Fluidigm, South San Francisco, CA, USA). The cycling program was 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 1 min at 60°C. The cycle threshold (Ct) values were obtained using the BioMark Gene Expression Data Analysis after automatic inspection for quality. Relative gene expression values were determined using the 2 ÀDDCt method of Livak and Schmittgen (Livak and Schmittgen 2001) . The average Ct values of cyclophilin D and hypoxanthine-guanine phosphoribosyltransferase were used as a reference; these housekeeping genes showed the least deviation in Ct values among the samples when six housekeeping genes (cyclophilin D, hypoxanthine-guanine phosphoribosyltransferase, TATA-box binding protein, b-actin, btubulin, and S19) were tested in a pre-assay. Genotype effects were measured by normalizing each gene expression value of KIV mice to the average of the gene expression values of WT mice (% expression of WT). Treatment effects were determined by normalizing each gene expression value to the average of the gene expression values of their respective controls (% expression of saline controls for antidepressant treatment and of SCT for EET). The information on primers and probes is described in Table S1 .
Statistical analysis
The data were analyzed using Prism (GraphPad Software, Inc., La Jolla, CA, USA). Student's t-tests were performed on the two data groups comparing KIV versus WT. To avoid type I errors (false positive) for measuring expression of many (24) genes, we confirmed the results by repeating the experiment with another cohort of mice (N = 10 per groups). The D'Agostino-Pearson omnibus normality tests were performed to analyze the data distribution for each tested gene in each genotype. All the data were normally distributed (p > 0.05). Two-way analyses of variance (ANOVA) were performed for detecting treatment and genotype effects, followed by post hoc Bonferroni multiple comparisons. Bonferroni correction would cause type II errors (false negative) when using a large number of testing groups (i.e., treatments); detection p-values are divided by the group number. To avoid type II errors, Student's t-tests were also performed on the two data groups comparing control versus treatment. Our specific hypotheses were tested when significant main effects were seen by two-way ANOVA, but post hoc Bonferroni analyses showed no significance. No discrepancies were found between Bonferroni's and Student's t-tests except for imipramine effects on hippocampal CHRNA7 and frontal cortex CHT in WT mice (see Results). These inconclusive data were further analyzed by the adjusted p-values (i.e., q-values) with the false discovery rate (Storey and Tibshirani 2003) using the classical one-stage method (Benjamini and Hockberg 1995) . Using preestablished criteria, we excluded data that showed > 2 standard deviations away from the mean to avoid data from technical errors. Statistical differences were considered significant at p < 0.05. Data are presented as mean AE standard error of mean.
Results
Detecting expression of 24 cholinergic genes
We first examined the mRNA levels of 24 cholinergic genes in the frontal cortex and hippocampus of KIV and control WT mice. These genes were muscarinic acetylcholine receptors 1-5 (CHRM1-5), nicotinic acetylcholine receptors a1-10 (CHRNA1-10), nicotinic acetylcholine receptors b1-4 (CHRNB1-4), nicotinic acetylcholine receptors d, e, and c (CHRND, CHRNE, and CHRNG), the choline transporter (CHT), and the choline acetyltransferase (ChAT). When compared to WT mice, KIV mice showed a significant increase in M2 muscarinic acetylcholine receptor (CHRM2) expression in the frontal cortex (p < 0.05), a significant decrease in M5 muscarinic acetylcholine receptor (CHRM5) expression in the hippocampus (p < 0.05), and significant decreases in nicotinic acetylcholine receptor alpha 5 (CHRNA5) in both frontal cortex (p < 0.01) and hippocampus (p < 0.01) ( Table S2 , N = 5 per group). No significant differences were observed between KIV and WT mice for the expression of the other 17 cholinergic genes in either the frontal cortex or the hippocampus, and no mRNA expression of nicotinic acetylcholine receptors d, e, and c 2b was detected (Table S2 , N = 5 per group).
Confirmation of our findings on CHRM2, CHRM5, and CHRNA5 To avoid type I errors (false positives) by measuring expression levels of a large number (24) of genes, we confirmed our results of expression changes of CHRM2, CHRM5, and CHRNA5 using another cohort of mice. We also re-measured the expression of ChAT, CHT, and CHRNA7 using a larger number of samples (N = 10 per group: 5 males and 5 females) to avoid type II errors (false negatives) and to confirm our results of no expression changes in comparison to previous studies that had shown BDNF effects on ChAT (Klein et al. 1999; Ward and Hagg 2000) and CHRNA7 (Massey et al. 2006; Fernandes et al. 2008) . The secondary BioMark qRT-PCR experiment reproduced our results of significant increases in CHRM2 expression in the frontal cortex (27% increase, p < 0.05), significant decreases in CHRM5 in the hippocampus (30% decrease, p < 0.01), and significant decreases in CHRNA5 in both frontal cortex (46% decrease, p < 0.001) and hippocampus (21% decrease, p < 0.01) in KIV mice when compared to WT mice (Fig. 1, N = 10) . These results indicated that deficiency of activity-dependent promoter IV-driven BDNF expression disturbs expression of these three cholinergic receptors in these target regions of the basal Effects of deficiency of activity-dependent promoter IV-Brainderived neurotrophic factor (BDNF) expression on selected cholinergic genes. KIV mice showed significantly increased mRNA levels of CHRM2 and significantly reduced mRNA levels of CHRNA5 in the frontal cortex (left) and significantly reduced levels of CHRM5 and CHRNA5 in the hippocampus, when compared with wild-type (WT) mice (N = 10 pairs). Results are expressed as mean AE SE *p < 0.05; **p < 0.01; ***p < 0.005 by Student's t-test.
forebrain cholinergic neurons. No significant differences between genotypes were observed again in mRNA expression levels for CHRNA7, CHT, and ChAT (p > 0.05, Fig. 1 ). No gender-specific effects were detected in any genes tested (males vs. females: p > 0.05 for CHRM2, CHRM5, CHRNA5, CHRNA7, CHT, and ChAT by Students's t-test; Table S3 ).
Treatment effects
We next asked whether expression levels of the affected cholinergic genes might be changed by chronic (21 days) antidepressant treatment (fluoxetine, phenelzine, duloxetine, and imipramine) or EET, because these treatments can partially or fully normalize depression-like behavior of KIV mice (Jha et al. 2011; Sakata et al. 2013b) . Our hypothesis was that these treatments might reverse the alteration in mRNA levels that serve as underlying mechanisms of the behavioral changes. First, we examined whether the treatments reduced CHRM2 expression, particularly in the frontal cortex of KIV mice. Two-way ANOVA showed significant effects of drug treatment on CHRM2 levels in the frontal cortex [F (4,42) = 4.11, p < 0.01] and the hippocampus [F (4,46) = 12.9, p < 0.001]. However, post hoc tests revealed that no treatment significantly affected CHRM2 expression in the frontal cortex of either genotype (p > 0.05 for each, Fig. 2a left, see Table S4 for statistics). In the hippocampus, imipramine treatment increased CHRM2 expression in both genotypes (at least p < 0.01 for each, Fig. 2a right) .
Second, we examined whether the treatments increased CHRM5 expression, particularly in the hippocampus of KIV mice. No significant treatment effects on CHRM5 expression were observed in the hippocampus of either genotype (p > 0.05), while duloxetine showed genotype differences (p < 0.05, WT vs. KIV, Fig. 2b right) . On the other hand, a significant treatment effect [F (4,40) = 8.9, p < 0.001] was found in the frontal cortex, where imipramine significantly increased CHRM5 expression in both WT and KIV mice (at least p < 0.05 for each, Fig. 2b left) .
Third, we examined whether the treatments increased CHRNA5 expression in the frontal cortex and hippocampus of KIV mice. Two-way ANOVA showed significant effects of environmental treatment [F (1,12) = 5.22, p < 0.05], genotype [F (1,12) = 7.12, p < 0.05], and a treatment x genotype interaction [F (1,12) = 5.47, p < 0.05] on frontal cortex CHRNA5. Post hoc tests revealed that EET significantly increased CHRNA5 expression in the frontal cortex of only KIV mice (p < 0.05, Fig. 2c left) , resulting in a significant genotype difference in the effect (p < 0.0.5). No significant treatment effects were observed other than the EET effects.
Fourth, we examined treatment effects on mRNA expression of CHRNA7, CHT, and ChAT, although the basal expression levels of these genes did not differ between genotypes. Interestingly, significant effects of environmental treatment were found on CHRNA7 [F (1,12) =17.3, p < 0.01], CHT [F (1,14) =7.6, p < 0.05], and ChAT [F (1,14) =11.8, p < 0.01] in the frontal cortex. EET significantly increased expression of these genes only in the KIV frontal cortex (at least p < 0.05 for each, Fig. 3a, b, and c, left) , where a genotype-specific difference was observed in the EET effects on CHRNA7 (p < 0.001). Imipramine also significantly increased CHRNA7 levels in the KIV frontal cortex (p < 0.05, Fig. 3a, left) . Two-way ANOVA and post hoc Bonferroni tests showed no other significant effects, although Student's t-test showed that imipramine significantly decreased levels of hippocampal CHRNA7 (p < 0.05) and frontal cortex CHT (p < 0.05) in WT mice. These inconclusive results were further assessed by false discovery rateadjusted p-values (q-values). q-values showed 0.31 for hippocampal CHRNA7 and 0.07 for frontal cortex CHT, which indicated a false positive and a trend of effects, respectively.
Discussion
Effects of promoter IV-BDNF deficiency
Nicotinic acetylcholine receptor (nAChR) a5
The most significant finding in this study was that deficiency of promoter IV-driven BDNF expression lead to significant reductions in mRNA levels of CHRAN5 in both the frontal cortex and hippocampus, suggesting its receptor dysfunctions in the regions. CHRNA5 encodes the nAChR a5 subunit, which forms a fast permeable ion channel in pentamer combinations of a 2/3 b 2/4 a5 (Conroy and Berg 1995; Ramirez-Latorre et al. 1996; Gotti et al. 2006; Berrettini and Doyle 2012) . The presence of a5 subunit increases acetylcholine sensitivity, calcium permeability, and fast desensitization (Ramirez-Latorre et al. 1996; Wang et al. 1996; Gerzanich et al. 1998) . Its presence also increases behavioral accuracy on attention tasks under highly demanding conditions (Bailey et al. 2010) . a5 is highly expressed in the frontal cortex and hippocampus, the critical regions for attention and learning (Wada et al. 1990; Salas et al. 2003; Winzer-Serhan and Leslie 2005) . The reduction in nAChR a5 levels in these regions of KIV mice, particularly in the frontal cortex (a 46% reduction), suggests that cognitive enhancement by acetylcholine/nicotine via nAChR a5 is compromised by the deficiency in activity-dependent BDNF expression via promoter IV. This has a clinical implication because deficiency of promoter IV-BDNF expression can occur under chronic social and physical stress (Tsankova et al. 2006; Fuchikami et al. 2009 ), early-life maltreatment (Roth et al. 2009) , and lack of neuronal activity (Shieh et al. 1998; Tao et al. 1998) , and is observed in many psychiatric conditions associated with cognitive impairments, including schizophrenia (Weickert et al. 2003; Hashimoto et al. 2005; Wong et al. 2010) , depression (Dwivedi et al. 2003; Keller et al. 2010; Hing et al. 2012) , and Alzheimer's disease (Phillips et al. 1991; Murray et al. 1994; Ferrer et al. 1999; Holsinger et al. 2000; Garzon et al. 2002) .
Interestingly, the CHRNA5 gene is well known for its polymorphisms associated with reduced cognitive performance (Winterer et al. 2010 ) and nicotine dependence Fig. 2 Effects of chronic drug and environmental treatments on mRNA expression of (a) CHRM2, (b) CHRM5, and (c) CHRNA5. Both wildtype (WT) and KIV mice received 21 days of four different types of antidepressants -fluoxetine (Flx), phenelzine (Phe), duloxetine (Dul), or imipramine (Imi) -or enriched environment treatment (EET). Expression changes because of the treatments are showed as % control for each genotype. Controls were saline treatment for the antidepressant treatments and a standard environmental condition treatment for EET. No treatment effects were observed except for significant inductions of CHRM2 and CHRM5 by imipramine in the hippocampus and frontal cortex, respectively, in both WT and KIV mice, and a significant induction of CHRAN5 by EET in the frontal cortex of KIV mice (N = 4-6 pairs). Bonferroni-corrected significance: *p < 0.05; ***p < 0.005 by two-way ANOVA with Bonferroni post hoc test. Other polymorphisms in the CHRNA5 promoter regions are also associated with reduced mRNA expression of CHRNA5 (Smith et al. 2011; Wang et al. 2013) . Reductions in expression and function of a5 nAChR are associated with reduced firing of GABA neurons and impaired social interactions in rodents (Koukouli et al. 2017) . Our results suggest that decreased levels of a5 nAChR because of the BDNF deficiency may, in part, account for the defective GABAergic functions observed in the prefrontal cortex (Sakata et al. 2009 ) and abnormal cognitive and emotional functions observed in KIV mice; that is, inflexible learning and depression/anxiety-like behavior (Sakata et al. 2010 (Sakata et al. , 2013a . Another plausible possibility is that the gene variations and expression regulation of a5 nAChR work together to alter the motivational and cognitive effects of nicotine/acetylcholine. In contrast to the well-studied polymorphism associations, the gene expression regulations between BDNF and CHRNA5 remain unstudied. To the best of our knowledge, this study is the first to present causal evidence that BDNF deficiency reduces transcription levels of CHRNA5. This finding offers a novel insight into the gene-environment interplay, that is, deficiency of promoter IV-BDNF expression, which can occur under environmental stress (Tsankova et al. 2006; Fuchikami et al. 2009; Roth et al. 2009 ) and lack of neuronal activity (Shieh et al. 1998; Tao et al. 1998) , leads to a5 nAChR-mediated cholinergic dysfunctions. Negative environments may therefore worsen nicotine dependence and cognitive dysfunction, particularly in subjects with the high-risk gene variations of functionally reduced CHRNA5/BDNF. Future studies can verify this gene expression -variation interplay.
Muscarinic acetylcholine receptors (mAChRs)
Additional novel findings included the small but significant increase in CHRM2 mRNA levels in the frontal cortex and the significant decrease in CHRMA5 mRNA in the hippocampus levels caused by the lack of promoter IVdriven BDNF expression. These findings suggest an additional disturbance in cholinergic functions via these muscarinic receptors in the subjects with promoter IV-BDNF deficiency. CHRM2 encodes M2 mAChR, a G i protein-coupled receptor that inhibits adenylate cyclase activity (Caulfield 1993; Felder 1995) . The M2 receptor is an autoreceptor that inhibits further release of acetylcholine from the pre-synaptic neurons into the synaptic cleft (Chau et al. 2001; Zhang et al. 2002) . Our result suggests that increased CHRM2 expression because of BDNF deficiency may limit acetylcholine release in the frontal cortex. Conversely, the increased CHRM2 expression could be a compensatory upregulation aimed at reducing a large amount of acetylcholine released under the BDNF deficiency. Further studies are needed to establish the acetylcholine levels and cholinergic functions in the frontal cortex. Interestingly, CHRM 2 has long been hypothesized to be involved in depression and cognitive inflexibility (Jeon et al. 2015) , which are the behavioral phenotypes observed in KIV mice (Sakata et al. 2010) . Human neuroimaging studies have shown a decrease (Cannon et al. 2006; Gibbons et al. 2009) or no change (Zavitsanou et al. 2005) in CHRM2 binding in the frontal cortex of subjects with mood disorders. Rodent studies have shown that blocking M2 mAChRs by an antagonist or deletion (knock-out) increases extracellular acetylcholine levels in the hippocampus and nucleus accumbens, and leads to depressive behavior (Chau et al. 2001) and impaired performance in the passive avoidance test (Chau et al. 2001; Tzavara et al. 2003) . Generally, hyper-cholinergic activation is hypothesized to cause depression-like behavior (Janowsky et al. 1972; Jeon et al. 2015) . Gene variations in CHRM2 have been also associated with a risk for major depression, major depressive syndrome and alcohol dependence (Wang et al. 2004; Luo et al. 2005; Hill et al. 2013) , alcohol dependence in subjects with schizophrenia (Kendler et al. 2011) , nicotine addiction (Mobascher et al. 2010) , and efficacy of cognitive therapy (Bakker et al. 2014) . Although the roles of M2 mAChRs in depression seem controversial (Cohen-Woods et al. 2009 ) and need further clarification, targeting the CHRM2 with antagonists or allosteric modulators may be efficacious as a treatment for mood disorders and possibly for cognitive flexibility.
CHRM5 encodes M5 mAChR, a G q -protein-coupled receptor that activates the phospholipase C-phosphatidylinositol-calcium signaling pathway (Caulfield 1993) . M5 mAChR mRNA is expressed in relatively selected regions/ cells (Weiner et al. 1990) , including the hippocampal CA1 pyramidal neurons (Vilaro et al. 1990 ) and the nigrostriatal dopaminergic neurons (Weiner et al. 1990; Reever et al. 1997) , where M5 mAChR controls prolonged dopamine release (Yeomans et al. 2001; Forster et al. 2002) . M5 mAChR is involved in reward-taking behavior; M5 knockout mice display reduced reward and withdrawal responses following morphine and cocaine administration (Fink-Jensen et al. 2003) . One possibility is that reduced expression of mAChR M5 in KIV mice may mediate their reduced responses for reward taking, that is, depression-like behavior (Sakata et al. 2013a) . Elucidation of how reduced gene expression of BDNF and CHRM5 affects the acetylcholine-induced dopaminergic function, and how this relates to affective and cognitive behavior, remains to be established in future studies.
Unchanged expression of other cholinergic genes
Our results showed no significant changes in expression of cholinergic genes other than CHRM2, CHRM5, and CHRNA5, either in the frontal cortex or the hippocampus, in the activity-dependent BDNF-deficient mice. This lack of changes in expression of CHRNA7 and ChAT were somewhat surprising, when compared to previous reports. CHRNA7 encodes a7 subunit, which forms a homomeric a7 nAChR (Gotti et al. 2006 ) with a relatively high permeability to calcium (Bertrand et al. 1993; Seguela et al. 1993) . The a7 subunit is widely expressed in the brain, including in the hippocampus and cortex (Seguela et al. 1993) . It is perhaps the most studied acetylcholine receptor related to BDNF. Previous studies have shown either an increase or a decrease in CHRNA7 expression, depending on the treatment conditions. Prolonged BDNF application (several hours to days) to cultured hippocampal neurons increases the clustering and the surface and intracellular pools of a7 nAChRs, particularly on GABAergic neurons (Kawai et al. 2002; Massey et al. 2006) ; however, acute BDNF application rapidly inhibits a7 nAChR-mediated currents in CA1 hippocampal interneurons (Fernandes et al. 2008) . Decreased binding or expression of both CHRNA7 and BDNF have been also reported in patients with cognitive dysfunction, such as schizophrenia (Freedman et al. 1995 (Freedman et al. , 1997 Weickert et al. 2003; Hashimoto et al. 2005; Wong et al. 2010; Parikh et al. 2016) , while both CHRNA7-and BDNF-mutant mice show cognitive inflexibility (Sakata et al. 2013a; Parikh et al. 2016) . Therefore, we predicted that a positive correlation would exist between BDNF and a7 nAChRs levels. However, our results showed no change in CHRNA7 expression in KIV mice, indicating that the BDNF deficiency does not affect the basal levels of a7 nAChR expression.
Similarly, KIV mice showed no significant reduction in ChAT. This finding contrasted with findings of previous studies that showed positive corrections between BDNF and ChAT levels. BDNF has been shown to increase ChAT expression and the release of constitutive acetylcholine when applied to cultured septal or basal forebrain neurons (Alderson et al. 1990; Auld et al. 2001) . Conversely, BDNF null (-/-) knockout mice have been shown to reduce ChAT staining levels at postnatal day 15 (Ward and Hagg 2000) . The reason for this difference in findings is unclear, but may be attributed to the extent of the BDNF deletion: ChAT levels may be affected by constitutive BDNF levels in null knockouts (entire deletion), but not by activity-dependent expression in KIV mice that retain constitutive BDNF levels driven by the other eight BDNF promoters. Another possibility is that age differences (during development vs. adult) may alter the effect of BDNF deficiency on ChAT expression.
CHT is a high-affinity choline transporter that mediates the uptake of choline for acetylcholine synthesis in cholinergic neurons (Sarter and Parikh 2005) . Activation of CHT functions is associated with attentional performance, whereas its dysregulation is associated with a decline in cholinergic transmission in Alzheimer's disease (Sarter and Parikh 2005) . We did not observe any changes in expression of CHT because of promoter IV-BDNF deficiency.
The results of the effects of BDNF deficiency and treatments on cholinergic genes are presented in Fig. 4 .
Treatment effects
Overall, our results suggested that the antidepressant treatments and EET were unlikely to affect the disturbed expression levels of CHRM2, CHRM5, and CHRNA5 caused by promoter IV-BDNF deficiency. This lack of effect suggests that these changes in cholinergic gene expression are involved in the previously observed improvement in antidepressive behavior because of the treatments (Sakata et al. 2013b) . The exception was that EET significantly increased CHRNA5 mRNA levels in the frontal cortex only in KIV mice (Fig. 2c) , suggesting that EET reverses the nAChR a5 dysfunctions in that brain region. The imipramine results were somewhat unexpected; imipramine treatment did not affect the altered expression of cholinergic genes caused by promoter IV-BDNF deficiency, but it increased expression of CHRM2 in the hippocampus and of CHRM5 in the frontal cortex in both WT and KIV mice. These results indicated that the induction of these genes by imipramine was not specific to promoter IV-BDNF deficiency or to normalize the altered expression caused by the deficiency. Imipramine is actually an antagonist of muscarinic receptors, particularly M2 (Raisman et al. 1979; Baldessarini 1996) . The expression changes of M2 and M5 by imipramine could be from the homeostatic changes in the cholinergic system after blocking/acting on the muscarinic receptors.
Interestingly, our results showed that EET and imipramine increased CHRNA7 expression in the frontal cortex, but only in KIV mice, whereas KIV mice showed no significant decreases in the basal expression levels of CHRNA7. The distribution of a7 mRNA expression strikingly overlaps with that of a5 in the hippocampal and cortical areas (WinzerSerhan and Leslie 2005) . The expression overlap raises the possibility that the induction of frontal cortex CHRNA7 by EET and imipramine may represent an additional compensation to normalize the dysfunctions caused by reduced CHRNA5 expression because of BDNF deficiency. a7 nAChR agonists or positive allosteric modulators has reported therapeutic potential as neuroprotective agents and cognitive enhancers (Levin et al. 2006) , and for treatments of psychiatric and neurological disorders (e.g., schizophrenia, ADHD, depression, and Alzheimer's disease) (Taly et al. 2009 ). These a7 nAChR-modulating compounds may compensate for a5 nAChR dysfunctions because of promoter IV-BDNF deficiency in those subjects.
Many antidepressant drugs, including fluoxetine, are potent non-competitive functional inhibitors of nAChR subtypes (Fryer and Lukas 1999) , and they also increase the extracellular levels of serotonin, another potent noncompetitive antagonist of a7 nAChR (Palma et al. 1996) . Therefore, we predicted that SSRI, SNRI, and tricyclic antidepressants would also inhibit a7 nAChRs and increase its adaptive mRNA induction. However, only the imipramine treatment results supported this hypothesis.
Our results also showed that EET increased CHT and ChAT expression in the frontal cortex of KIV mice, whereas the basal expression of these genes was not altered in KIV mice compared to WT mice. The increases in acetylcholine synthesis and transport by EET may represent a compensation for the reduced nicotinic cholinergic functions because of promoter IV-BDNF deficiency. Our observed lack of changes in ChAT expression by EET in WT mice agrees with a previous study that showed no changes in hippocampal ChAT activity in response to EET (Dhanushkodi et al. 2007 ), but disagrees with another study showing its increase (Wang et al. 2016) . We also found the trend that imipramine reduced the expression of CHT in the WT frontal cortex, which needs to be further confirmed. The reason is unknown, but this reduction may reflect a homeostatic feedback operation because of the anti-cholinergic functions of imipramine.
Overall, EET effects were the most prominent of all the treatments, inducing CHRNA5, CHRNA7, CHT, and ChAT in the frontal cortex of KIV mice only, and thereby suggesting that EET may be particularly efficacious in subjects with BDNF deficiency (Fig. 4) . The specific and strong effects of EET are in accordance with the findings of our previous study -EET reversed depression-like behavior of KIV mice (Jha et al. 2011 ) more effectively than antidepressant treatments (Sakata et al. 2013b) . One possibility is that enhancement of the cholinergic system underlies the behavioral effects of EET, particularly via increasing motivation and cognitive flexibility, even though increases in cholinergic activity is historically hypothesized to cause depression (Janowsky et al. 1972) . However, the cholinergic hypothesis of depression may need revision, based on the detailed receptor-specific functional changes and interpretations. Patients with mood disorders can respond supersensitively to a cholinergic challenge, where the cholinergic supersensitivity is related to stress intolerance rather than the depressive state itself (Fritze 1993) . Hypersensitivity may arise from an imbalanced expression of acetylcholine receptor subtypes. For example, increased expression of autoreceptor M2 AChRs in the frontal cortex of subjects with promoter IV-BDNF deficiency may cause a decrease in basal extracellular levels of acetylcholine. These reduced basal levels may in turn increase the cell-surface expression of AChRs as a way to increase sensitivity to acetylcholine. However, upon release of acetylcholine, the reduction in a5 nAChR expression may prohibit a5 nAChR-specific neuronal functions in subjects with BDNF deficiency. EET may reverse this dysfunction by up-regulation of a5 nAChR as well as a7 nAChR, ChAT, and CHT.
The cholinergic system also interplays with other systems, namely the monoaminergic and GABAergic systems (Janowsky et al. 1983; Kawai et al. 2002; Massey et al. 2006; Koukouli et al. 2017) . These systems are also involved in depression (Janowsky et al. 1983; Luscher et al. 2011) and are also disturbed by the BDNF deficiency in KIV mice (Tripp et al. 2012; Sakata and Duke 2014) . A complex interplay likely occurs involving the altered cholinergic expression by the BDNF deficiency and the treatment effects. Further studies are needed to uncover the functional changes in the cholinergic system under the BDNF deficiency and their relationships to other neurotransmitter systems.
Cholinergic system as treatment target
The cholinergic system, particularly nAChRs, is gaining interest in the development of treatments for various nervous system disorders, such as Alzheimer's disease, age-associated memory impairment, schizophrenia, depression, ADHD, and tobacco addiction (Levin et al. 2006; Arneric et al. 2007; Romanelli et al. 2007; Taly et al. 2009 ). Positive therapeutic effects of nicotinic agonists have been observed in initial studies on a variety of cognitive dysfunctions (Levin et al. 2006) . Nevertheless, only compounds showing selectivity between a4b2 and a7 receptors have been obtained (Romanelli et al. 2007) . To the best of our knowledge, no compounds modulating a5 are yet available or have been tested to treat nervous system disorders. Our results showing a reduction in CHRNA5 in KIV mice suggest that the use of drugs targeting the function and expression of a5 nAChR (e.g., modulators increasing Ca 2+ permeability and blockers of its desensitization and internalization) could be a beneficial new strategy for treating cognitive dysfunctions and mood disorders caused by BDNF deficiency. These a5 nAChR compounds may become add-on drugs to supplement the already existing therapeutic nicotinic agonists targeting a4b2 and a7 (Levin et al. 2006) . In addition, biological tools to study CHRNA5 protein levels/function, such as a5-specific agonists/antagonists and a5-specific antibodies, are also currently unavailable. This is likely the reason why the protein levels and functions of a5 remain unstudied in comparison to other nAChR subunits, such as a7 and a4b2 (Parikh et al. 2016) . Developing these tools may greatly advance our understanding of the mechanisms by which BDNF deficiency leads to cholinergic dysfunctions in the frontal cortex and hippocampus.
The potent antimuscarinic effects of tricyclic antidepressants, including imipramine have been thought primarily to produce adverse side effects during antidepressant drug treatment (Baldessarini 1996; Pacher and Kecskemeti 2004) . However, a more recent study has shown that blocking M1 and M2 muscarinic receptor subtypes produces antidepressant-like effects of the rapidly acting antidepressant scopolamine (Witkin et al. 2014) . Our results suggest that novel drugs that selectively block M2, but activate M5 mAChRs, and that have negligible effects on the peripheral nervous system, might produce more rapid and robust clinical improvement in patients with mood disorders.
Study limitations
The relatively limited effects of the antidepressant treatments may be because of the drug administering method, i.p. injection. We used this method based on the previous studies (see Methods). However, daily i.p. injection could be stressful to the animal, and the stress could counteract the treatment effects. Future studies using other (e.g., oral) methods may confirm the drug effects on the cholinergic system, although either i.p. injection and oral administration of the four drugs has been shown not to rescue the reduced BDNF levels in the KIV hippocampus despite our initial hypothesis (Sakata et al. 2013b) .
Another caveat of this study is that we only measured mRNA levels. The levels of mRNA do not necessarily reflect protein levels, but could reflect a compensational up-regulation of the dysfunction of the cholinergic molecules. For example, increased M2 mAChRs in KIV mice may reflect reduced protein levels of the M2 autoreceptor and the excess levels of released acetylcholine under BDNF deficiency, which compensate for the dysfunctions in nicotinic acetylcholine receptor a5. Future studies are expected to clarify the levels of acetylcholine and these cholinergic protein levels/locations in the frontal cortex and hippocampus, as well as the functional changes, through the use of specific agonists/antagonists. This clarification will further advance our understanding of the effects of BDNF deficiency and treatments on the cholinergic system.
Conclusions
Our goal in this study was to determine the effects of promoter IV-BDNF deficiency and treatments on cholinergic gene expression. Our results provided causal evidence that promoter IV-driven BDNF reduced CHRNA5 gene expression in both frontal cortex and hippocampus, increased CHRM2 in the frontal cortex, and decreased CHRM5 in the hippocampus. This disturbance of cholinergic gene expression by BDNF deficiency may be one important mechanism that links stress and lack of activity to the defective behavioral phenotypes observed in KIV mice; namely, inflexible learning and depression-like behavior caused by impaired attention and response inhibition. Our findings also indicate that chronic treatments with fluoxetine, phenelzine, duloxetine, imipramine, and EET did not affect the disturbed expression of these genes, except that EET increased CHRNA5 mRNA levels only in the frontal cortex of KIV mice. EET also up-regulated mRNA levels of CHRNA7, CHT, and ChAT in the frontal cortex of KIV mice. These results suggested a potential cholinergic recovery in the frontal cortex in the BDNF-deficient condition by EET. The imipramine effect was most prominent among the four different types of antidepressants; it up-regulated hippocampal CHRM2 and frontal cortex CHRM5 in both genotypes, and frontal cortex CHRNA7 only in KIV mice, likely reflecting its anticholinergic function. Future studies are needed to address the detailed localization and the consequent dysfunction of the disturbed cholinergic expression caused by the deficiency of activity-dependent BDNF and its relationship with cognitive functions and affective disorders. It would be also interesting to examine gene variationexpression relationships of CHRNA5, CHRM2, and CHRM5 in patients who show reduced BDNF levels (e.g., schizophrenia, depression, Alzheimer's disease), correlating with cognitive function.
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